Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

The hearing test that could see what standard exams miss

NCT ID NCT07738549

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study explores why some adults struggle to understand speech in noisy environments even when their standard hearing tests are normal. Researchers will use a battery of advanced hearing tests—including extended high-frequency audiometry, inner ear electrical responses, and brain wave measurements—to look for subtle damage in the ear or auditory pathways. The goal is to better identify and characterize hidden hearing loss, potentially leading to more accurate diagnosis and future management strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Audiological and electrophysiological diagnostic tests, including extended high-frequency audiometry, electrocochleography, otoacoustic emissions, and auditory brainstem responses
What this could lead to
If successful, this could lead to better diagnostic tools for hidden hearing loss, helping people who struggle to hear in noisy places despite normal standard hearing tests.
What could go wrong
This is a diagnostic study, not a treatment trial, so it won't directly improve hearing. The tests may not fully capture the underlying causes, and results may not apply to everyone with hearing complaints.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adult patients (age \> 18 years). Patients affiliated with a social security/health insurance system. Patients consulting the ENT department for hearing difficulties despite normal conventional pure-tone and speech audiometry performed in quiet. Patients whose native language is French. Patients who have received oral and written information about the study and have provided free and informed consent. Normal otoscopic examination: No external auditory canal obstruction. No history of middle ear surgery (except childhood tympanostomy tube placement). Presence of a translucent tympanic membrane in at least one quadrant, with no tympanic membrane perforation. No signs of active otitis infection. No signs of cholesteatoma. Well-ventilated middle ear cavity confirmed by conventional tympanometry at 226 Hz. \- Inclusion criteria for the control group: Adult patients aged between 18 and 25 years. Patients seen during an ENT consultation at Clermont-Ferrand University Hospital, without any hearing complaints. Patients with normal conventional pure-tone audiometry performed in quiet, defined as hearing thresholds between 0 and 20 dB HL across frequencies from 0.25 to 8 kHz, according to BIAP 2017 criteria. No selection bias is expected, as normal hearing is defined as hearing thresholds between 0 and 20 dB HL (BIAP 2017). This age range was selected because it provides the highest likelihood of including individuals with normal auditory function. -Exclusion criteria : Patients under legal guardianship, curatorship, judicial protection, or deprived of liberty. Pregnant or breastfeeding women. History of language disorders. Abnormal pure-tone audiometry in quiet, defined as: Mean pure-tone hearing loss \> 20 dB HL, or At least one frequency threshold \> 20 dB HL. Abnormal speech audiometry, defined as: Speech reception threshold on Lafon disyllabic word lists (male voice) \> 20 dB HL, and/or Maximum speech intelligibility score of 100% obtained at a level \> 40 dB HL. Refusal to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Surdity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63000, France